Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study

Mei-Hsuan Lee,1 Hwai-I. Yang,1,2,3 Sheng-Nan Lu,4 Chin-Lan Jen,1 San-Lin You,1 Li-Yu Wang,5 Chih-Hao Wang,6 Wei J. Chen,7 Chien-Jen Chen,1,7 and for the R.E.V.E.A.L.-HCV Study Groupa

1Genomics Research Center, Academia Sinica, Taipei; 2Molecular and Genomic Epidemiology Center, China Medical University Hospital, Taichung; 3Graduate Institute of Clinical Medical Science, China Medical University, Taichung; 4Department of Gastroenterology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung; 5MacKay Medical College, Taipei; 6Department of Cardiology, Cardinal Tien Hospital, Taipei; and 7Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan

(See the editorial commentary by Nelson, on pages 461–3.)

Background. The study aimed to evaluate the risk of hepatitis C virus (HCV) infection on hepatic and extrahepatic deaths.

Methods. A cohort of 23,820 adults aged 30–65 years old were enrolled during 1991–1992. The seromarkers hepatitis B surface antigen (HBsAg), anti-HCV, and serum HCV RNA levels at study entry were tested. The vital status was ascertained through computerized linkage with national death certification profiles from 1991 to 2008.

Results. There were 19,636 HBsAg-seronegatives, including 18,541 anti-HCV seronegatives and 1,095 anti-HCV seropositives. Among anti-HCV seropositives, 69.4% had detectable serum HCV RNA levels. There were 2,394 deaths that occurred during an average follow-up period of 16.2 years. Compared with anti-HCV seronegatives, anti-HCV seropositives had higher mortality from both hepatic and extrahepatic diseases, showing multivariate-adjusted hazard ratio (95% confidence interval) of 1.89 (1.66–2.15) for all causes of death; 12.48 (9.34–16.66) for hepatic diseases; 1.35 (1.15–1.57) for extrahepatic diseases; 1.35 (1.15–1.57) for hepatic diseases; 1.50 (1.10–2.03) for circulatory diseases; 2.77 (1.49–5.15) for nephritis, nephrotic syndrome, and nephrosis; 4.08 (1.38–12.08) for esophageal cancer; 4.19 (1.18–14.94) for prostate cancer; and 8.22 (1.36–49.66) for thyroid cancer. Anti-HCV seropositives with detectable HCV RNA levels had significantly higher mortality from hepatic and extrahepatic diseases than anti-HCV seropositives with undetectable HCV RNA.

Conclusions. Monitoring HCV RNA in anti-HCV seropositives is essential for the prediction of mortality associated with hepatitis C.

Hepatitis C virus (HCV) infects more than 170 millions people worldwide [1]. There is a considerable geographical variation in seroprevalence of antibodies against HCV (anti-HCV) throughout the world, with approximately 1.3% in developed countries and 2.6% in developing countries [2]. HCV is well recognized to cause fatal liver diseases, including liver cirrhosis and hepatocellular carcinoma. Individuals infected with HCV are often asymptomatic and not aware of their illness until severe and irreversible liver diseases occur. Several long-term follow-up studies examined the sequelae associated with HCV infection were often limited to specific populations [3–5]. The impacts of HCV infections, particularly among those with viremia persistently, on the mortality of liver diseases...
have been less evaluated for the general population in the community.

In addition to hepatic diseases, HCV infection has also been found to be involved in a variety of extrahepatic diseases. Several clinical manifestations have been reported to be linked with HCV infection [6]. Negative-strand HCV RNA by strand-specific reverse transcriptase polymerase reaction, an evidence for viral replication, has been detected in extrahepatic tissues [7]. Antiviral therapy has been documented to decrease the rate of fibrosis progression in patients with chronic HCV infection [8], suggesting extrahepatic diseases may become an important health burden in HCV-infected patients. However, the HCV-associated mortality from extrahepatic diseases has seldom been assessed in long-term follow-up studies on community-based cohorts. The associations between the seropositivity of HCV RNA and the mortality from extrahepatic diseases have never been evaluated.

The Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer (R.E.V.E.A.L)-HCV study is a prospective community-based cohort study in Taiwan, which provides a large number of participants for investigations of natural history and long-term disease burden of chronic hepatitis C [9]. In this analysis, we compared both hepatic and extrahepatic mortality rates predicted by seromarkers of HCV infection, including anti-HCV and HCV RNA at study entry.

**METHODS**

**Study Cohort Enrollment**

This community-based cohort study invited 89,293 (47,079 male and 42,214 female) residents aged 30–65 years to participate in 1991–1992. They were living in 7 townships located in Taiwan. Initial invitations were made by mailed letters, and follow-up telephone calls were subsequently made to those who did not respond to the initial invitation. Individuals willing to participate were personally interviewed to provide detail information to assure their complete understanding of the informed consent. A total of 23,820 (11,973 men and 11,847 women) agreed to participate with written informed consent. The demographic characteristics such as sex and age of participants were quite similar to those who did not participate [10]. All participants received health examinations at enrollment, and those with abnormal findings of serological or biochemical tests were referred to hospitals or clinics for prompt managements. All participants were regularly followed up until 31 December 2008. A detailed description of the study population and data collection has been documented previously [11]. A total of 19,636 participants seronegative for hepatitis B surface antigen (HBsAg) were included in this analysis. This study was approved by the institutional review board of the College of Public Health, National Taiwan University in Taipei.

**Questionnaire Interview and Blood Collection**

All participants were personally interviewed by public health nurses with structured questionnaires. The collected information included demographic characteristics, habits of cigarette smoking and alcohol consumption, and personal history of major diseases. Each participant provided a 10 mL blood sample with a standard sterile syringe for various serological and biochemical tests. Blood samples were separated on the day of collection and kept at −70°C until assay.

**Laboratory Examinations**

Serological markers, including hepatitis B surface antigen (HBsAg) and anti-HCV, were tested by commercial assays as described previously [11]. Samples seropositive for anti-HCV were further examined for HCV RNA by polymerase chain reaction using the COBAS TaqMan HCV test, v2.0 (Roche Diagnostics, Indianapolis, NJ). The detection limit for COBAS TaqMan HCV test was 25 IU/mL.

**Ascertainment of Causes of Death**

In Taiwan, it is mandatory to register deaths of all citizens in a computerized database. The National Death Certification Registry profile contains the information on the date and causes of death, which has been used for several significant outcome-based research studies [10, 12]. By law, certificates must be registered within 1 month after death in Taiwan. All death certificates were coded and reviewed by medical registrars in the central office. The death certification system keeps updated and complete information on the vital status and causes of death of all inhabitants in Taiwan. The national identification number, date at birth, and sex were used as the linking variables to double-check the vital status and causes of death of study participants from the national death certification system. The International Classification of Diseases, Version 9 (ICD-9) codes were identified and utilized for subsequent analyses. All deaths occurring between study entry and 31 December 2008 were included.

**Statistical Analysis**

Mortality rates of both hepatic and extrahepatic diseases were evaluated systematically by stratifying anti-HCV serostatus. The ICD-9 codes were identified and grouped according to anatomic sites for statistical analyses. However, some specific causes of death with small numbers of deaths (<3) were not tested for their associations with HCV infection and were not listed in the tables (except thyroid gland cancer, which was previously reported to be associated with HCV) [13]. The person-years of follow-up were calculated for each participant as the time from the enrollment date either to the date at death or to 31 December 2008 for those who were still alive then. Mortality rates of specific cause were expressed per 100,000 person-years.
The cumulative risk of dying from specific cause of death in anti-HCV seronegatives and seropositives was estimated by the Kaplan–Meier method and the statistical significance of the difference was examined by log-rank test. Cox proportional hazard models were used to estimate age-sex–adjusted and multivariate-adjusted hazard ratio (HR) with 95 percent confidence intervals (95% CIs) of specific cause of deaths for HCV infection. Statistical significance levels were determined by a 2-sided P value of .05. All analyses were performed using the SAS statistical software package (release 9.1; SAS Institute Inc, Cary, NC).

RESULTS

There were 1095 anti-HCV seropositives and 18 541 anti-HCV seronegatives in this study. The mean age in this cohorts was 47.6 years old at study entry (47.4 years in anti-HCV seronegatives and 50.8 years in anti-HCV seropositives; P < .01). There were 9060 (48.9%) males in anti-HCV seronegatives and 50.8 years in anti-HCV seropositives; the average follow-up period was 16.2 years. A total of 2394 deaths occurred during 317 742 person-years follow-up, giving an overall mortality of 753.4 per 100 000 person-years among HBsAg-seronegative participants. Table 1 shows the mortality rates and multivariate-adjusted HRs with 95% CIs of specific causes of death by serostatus of anti-HCV at study entry. Liver cancer and chronic liver diseases and cirrhosis contributed to most of the hepatic diseases. The proportionality assumption (nonchanging HRs over time) of Cox models was examined, and the assumption was not violated. Participants seropositive for anti-HCV had an increased risk of dying from hepatic diseases with a multivariate-adjusted HR (95% CI) of 12.48 (9.34–16.66). The mortality rate of extrahepatic diseases per 100 000 person-years was 671.6 for anti-HCV seronegatives and 1054.8 for anti-HCV seropositives. Among the extrahepatic causes of death, 1383 (68.5%) and 124 (69.3%) were noncancer deaths for participants seronegative and seropositive for anti-HCV, respectively. The mortality rates per 100 000 person-years for extrahepatic noncancer causes were 459.8 for anti-HCV seronegatives and 730.7 for anti-HCV seropositives with a multivariate-adjusted HR (95% CI) of 1.38 (1.15–1.66). Participants seropositive for anti-HCV had a higher risk of dying from circulatory diseases and renal diseases with a multivariate-adjusted HR (95% CI) of 1.50 (1.10–2.03) and 2.77 (1.49–5.15), respectively, compared with anti-HCV–seronegative participants.

Table 1. Mortality Rates (Per 100 000 Person-Years) and Crude and Adjusted Hazard Ratios of Specific Causes of Death by Serostatus of Antibodies Against Hepatitis C Virus (Anti-HCV) at Study Entry

<table>
<thead>
<tr>
<th>Causes of Death (ICD-9 Codes)</th>
<th>Anti-HCV (−), N = 18 541 (300 772 person-years)</th>
<th>Anti-HCV (+), N = 1095 (16 970 person-years)</th>
<th>Age-Sex-Adjusted Hazard Ratio (95% CI)</th>
<th>Multivariate-Adjusted Hazard Ratioa (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All causes</td>
<td>Death No. 2132, Mortality Rate 708.8</td>
<td>Death No. 262, Mortality Rate 1543.9</td>
<td>Crude Hazard Ratio (95% CI) 2.21 (1.95–2.51)</td>
<td>1.87 (1.64–2.12) 1.89 (1.66–2.15)</td>
</tr>
<tr>
<td>Hepatic diseases (155, 570–573)</td>
<td>112, Mortality Rate 37.2</td>
<td>83, Mortality Rate 489.1</td>
<td>13.35 (10.05–17.73)</td>
<td>11.83 (8.88–15.76) 12.48 (9.34–16.66)</td>
</tr>
<tr>
<td>Liver cancer (155)</td>
<td>50, Mortality Rate 16.6</td>
<td>65, Mortality Rate 383.0</td>
<td>23.52 (16.27–34.01)</td>
<td>20.56 (14.17–29.84) 21.63 (14.83–31.54)</td>
</tr>
<tr>
<td>Chronic liver diseases and cirrhosis (571–572)</td>
<td>58, Mortality Rate 19.3</td>
<td>18, Mortality Rate 106.1</td>
<td>5.57 (3.28–9.46)</td>
<td>5.06 (2.97–8.63) 5.38 (3.15–9.19)</td>
</tr>
<tr>
<td>Other disorders of liver (570, 573)</td>
<td>4, Mortality Rate 1.3</td>
<td>0, Mortality Rate 0.0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Extrahepatic diseases</td>
<td>2020, Mortality Rate 671.6</td>
<td>179, Mortality Rate 1054.8</td>
<td>1.59 (1.37–1.86)</td>
<td>1.34 (1.15–1.56) 1.35 (1.15–1.57)</td>
</tr>
<tr>
<td>Cancers (140–239 except 155)</td>
<td>637, Mortality Rate 211.8</td>
<td>55, Mortality Rate 324.1</td>
<td>1.56 (1.18–2.05)</td>
<td>1.31 (1.00–1.73) 1.32 (1.00–1.74)</td>
</tr>
<tr>
<td>Diabetes mellitus (250)</td>
<td>183, Mortality Rate 60.8</td>
<td>18, Mortality Rate 106.1</td>
<td>1.78 (1.10–2.89)</td>
<td>1.37 (0.84–2.23) 1.49 (0.91–2.42)</td>
</tr>
<tr>
<td>Circulatory diseases (390–459)</td>
<td>477, Mortality Rate 158.6</td>
<td>46, Mortality Rate 271.1</td>
<td>1.73 (1.28–2.34)</td>
<td>1.42 (1.06–1.93) 1.50 (1.10–2.03)</td>
</tr>
<tr>
<td>Respiratory diseases (460–519)</td>
<td>165, Mortality Rate 54.9</td>
<td>8, Mortality Rate 47.1</td>
<td>0.87 (0.43–1.78)</td>
<td>0.73 (0.36–1.48) 0.71 (0.35–1.44)</td>
</tr>
<tr>
<td>Nephritis, nephrotic syndromes and nephrosis (580–589)</td>
<td>69, Mortality Rate 22.9</td>
<td>12, Mortality Rate 70.7</td>
<td>3.13 (1.70–5.78)</td>
<td>2.61 (1.41–4.83) 2.77 (1.49–5.15)</td>
</tr>
</tbody>
</table>

Abbreviation: CI, confidence interval.

* All hazard ratios were adjusted for age, sex, cigarette smoking, alcohol drinking, betel nuts chewing, and central obesity; hazard ratios for all causes of death, hepatic diseases, extrahepatic diseases, and nephritis, nephrotic syndromes and nephrosis were additionally adjusted for personal history of diseases (diabetes, hypertension, heart diseases, cerebrovascular disease); hazard ratios for diabetes mellitus and circulatory diseases were additionally adjusted for personal history of diseases and baseline serum levels of cholesterol and triglycerides.
Table 2. Mortality Rates (Per 100 000 Person-Years) and Crude and Adjusted Hazard Ratios of Extrahepatic Cancers by Serostatus of Antibodies Against Hepatitis C Virus (Anti-HCV) at Study Entry

<table>
<thead>
<tr>
<th>Cancer Site (ICD-9 codes)</th>
<th>Death No. (Person-Years)</th>
<th>Mortality Rate</th>
<th>Death No. (Person-Years)</th>
<th>Mortality Rate</th>
<th>Crude Hazard Ratio (95% CI)</th>
<th>Age-Sex-Adjusted Hazard Ratio (95% CI)</th>
<th>Multivariate-Adjusted Hazard Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasopharynx (147)</td>
<td>33 (18 541)</td>
<td>11.0</td>
<td>3 (1095)</td>
<td>17.7</td>
<td>1.60 (0.49–5.23)</td>
<td>1.54 (0.47–5.05)</td>
<td>1.50 (0.50–4.92)</td>
</tr>
<tr>
<td>Esophagus (150)</td>
<td>19 (300 772)</td>
<td>6.3</td>
<td>4 (16 970)</td>
<td>23.6</td>
<td>3.79 (1.29–11.14)</td>
<td>3.78 (1.28–11.17)</td>
<td>4.08 (1.38–12.08)</td>
</tr>
<tr>
<td>Colon (153)</td>
<td>44 (16 970)</td>
<td>14.6</td>
<td>4 (16 970)</td>
<td>23.6</td>
<td>1.65 (0.59–4.60)</td>
<td>1.40 (0.50–3.89)</td>
<td>1.43 (0.51–3.99)</td>
</tr>
<tr>
<td>Gallbladder and extrahepatic bile ducts (156)</td>
<td>26 (16 970)</td>
<td>8.6</td>
<td>3 (16 970)</td>
<td>17.7</td>
<td>2.12 (0.64–6.99)</td>
<td>1.74 (0.52–5.77)</td>
<td>1.79 (0.54–5.94)</td>
</tr>
<tr>
<td>Trachea, bronchus and lung (162)</td>
<td>185 (16 970)</td>
<td>61.5</td>
<td>11 (16 970)</td>
<td>64.8</td>
<td>1.08 (0.59–1.98)</td>
<td>0.92 (0.50–1.69)</td>
<td>0.90 (0.49–1.66)</td>
</tr>
<tr>
<td>Prostate (185)b</td>
<td>12 (16 970)</td>
<td>4.0</td>
<td>3 (16 970)</td>
<td>17.7</td>
<td>5.45 (1.54–19.30)</td>
<td>4.37 (1.23–15.51)</td>
<td>4.19 (1.18–14.94)</td>
</tr>
<tr>
<td>Thyroid gland (193)c</td>
<td>3 (16 970)</td>
<td>1.0</td>
<td>2 (16 970)</td>
<td>11.8</td>
<td>10.53 (1.76–63.04)</td>
<td>7.81 (1.29–47.49)</td>
<td>8.22 (1.36–49.66)</td>
</tr>
<tr>
<td>Leukemia (204–208)</td>
<td>14 (16 970)</td>
<td>4.7</td>
<td>3 (16 970)</td>
<td>17.7</td>
<td>3.86 (1.11–13.43)</td>
<td>3.29 (0.94–11.54)</td>
<td>3.18 (0.91–11.16)</td>
</tr>
</tbody>
</table>

Abbreviation: CI, confidence interval.

* Hazard ratios for nasopharynx cancer and esophagus cancer were adjusted for age, sex, cigarette smoking, alcohol drinking, and betel nuts chewing; hazard ratios for colon cancer, gallbladder and extrahepatic bile ducts cancer, and trachea, bronchus, and lung cancer were adjusted for age, sex, cigarette smoking, alcohol drinking, betel nuts chewing, and central obesity; hazard ratio for prostate cancer was adjusted for age, cigarette smoking, alcohol drinking, betel nuts chewing and central obesity; hazard ratio for thyroid cancer was adjusted for age and central obesity; and hazard ratio for leukemia was adjusted for age, sex, and central obesity.

b Men only.

c All cases were women.

Table 2 shows the mortality rates of cancers in the participants. Anti-HCV–seropositive participants had a higher mortality from esophagus cancer, prostate cancer, and thyroid cancer than anti-HCV–seronegative ones, showing a multivariate-adjusted HR (95% CI) of 4.08 (1.38–12.08), 4.19 (1.18–14.94), and 4.19 (1.18–14.94), respectively.

In this study, 975 anti-HCV seropositives had retrievable samples for serum HCV RNA test. Among them, there were 298 (30.6%) undetectable and 677 (69.4%) detectable for HCV RNA. Figure 1 shows the cumulative mortality from all causes, hepatic diseases, and extrahepatic diseases by seropositivity of anti-HCV and HCV RNA. Anti-HCV seropositives with detectable serum HCV RNA levels had a significantly higher risk of dying from all causes of death, hepatic diseases, and extrahepatic diseases than anti-HCV seropositives with undetectable serum HCV RNA and anti-HCV seronegatives (P < .001).

Figure 2 shows the cumulative mortality from liver cancer and chronic liver diseases and cirrhosis by seropositivity of anti-HCV and HCV RNA. After 18 years of follow-up, the cumulative liver cancer mortality was 0.3%, 1.6%, and 10.4% for anti-HCV seronegatives, anti-HCV seropositives with undetectable serum HCV RNA levels, and anti-HCV seropositives with detectable serum HCV RNA, respectively (P < .001). There was no case that died from chronic liver diseases and cirrhosis among participants seropositive for anti-HCV with undetectable serum HCV RNA. The cumulative mortality of chronic liver diseases and cirrhosis with detectable serum HCV RNA was 0.3% for anti-HCV seronegatives and 2.8% for anti-HCV seropositives.

Figure 3 shows the cumulative mortality from circulatory and renal diseases by seropositivity of anti-HCV and HCV RNA. The cumulative mortality from circulatory diseases was 2.9%, 3.5%, and 5.0% for anti-HCV seronegatives, anti-HCV seropositives with undetectable serum HCV RNA, and anti-HCV seropositives with detectable serum HCV RNA, respectively (P < .01). The corresponding cumulative mortality from nephritis, nephrotic syndrome, and nephrosis was 0.47%, 0.92%, and 1.48%, respectively (P < .01).

Table 3 shows multivariate-adjusted HRs (95% CIs) of dying from selected causes of death by serostatus of anti-HCV and HCV RNA at study entry. There was a significantly increasing trend in mortality from anti-HCV seronegatives, anti-HCV seronegatives with undetectable serum HCV RNA, to anti-HCV seropositives with detectable serum HCV RNA for most of the diseases. There was no death from chronic liver disease and cirrhosis, esophagus cancer, prostate cancer, and thyroid cancer among anti-HCV seropositives with undetectable serum HCV RNA at study entry.

**DISCUSSION**

An increasing HCV-related mortality from 1.09 to 2.40 per 100 000 person-years has been reported in the United States.
from 1995 to 2004 [14]. The predicted mortality over a 20-year period is expected to continue to rise [15], suggesting the health burden related to HCV infection will be substantially considerable in the foreseeable future.

The detectable serum HCV RNA level is a marker for active replication of HCV, and 52%–80% of serum samples seropositive for anti-HCV were found to have detectable serum levels of HCV RNA in previous reports [16–18]. We found that anti-HCV seropositives with detectable serum HCV RNA had an increased risk of dying from all causes of death, whereas the risk for anti-HCV seropositives with negative HCV RNA was similar to the risk for anti-HCV seronegatives. The results implied that chronic hepatitis C patients with active virus infection may benefit from antiviral treatment to reduce their overall mortality. This finding was in line with another prospective study conducted in Japan, which showed that 28.0% from 1995 to 2004 [14]. The predicted mortality over a 20-year period is expected to continue to rise [15], suggesting the health burden related to HCV infection will be substantially considerable in the foreseeable future.

The detectable serum HCV RNA level is a marker for active replication of HCV, and 52%–80% of serum samples seropositive for anti-HCV were found to have detectable serum levels of HCV RNA in previous reports [16–18]. We found that anti-HCV seropositives with detectable serum HCV RNA had an increased risk of dying from all causes of death, whereas the risk for anti-HCV seropositives with negative HCV RNA was similar to the risk for anti-HCV seronegatives. The results implied that chronic hepatitis C patients with active virus infection may benefit from antiviral treatment to reduce their overall mortality. This finding was in line with another prospective study conducted in Japan, which showed that 28.0%
anti-HCV seropositives with HCV viremia (detectable HCV core antigen or HCV RNA in serum) and 17.9% anti-HCV seropositives without HCV viremia died from any cause during an average follow-up period of 8.2 years [19]. However, the cumulative mortality for anti-HCV seropositives without viremia in the Japanese study was 5% higher than that in the R.E.V.E.A.L.-HCV study. This may have resulted from differences in the age and sex composition and clinical characteristics of HCV-infected participants between the 2 studies. Possibly, the different detection limit of the HCV RNA assays might also have contributed to the discrepancy.

In this study, the cumulative hepatic disease mortality 18 years after enrollment was as high as 9.3% for anti-HCV seropositives. It has been reported that the cumulative mortality from hepatic diseases among anti-HCV seropositives was 0.35%–5% after 10–25 years of follow-up [3–5, 20]. However, most previous long-term follow-up studies enrolled relatively young and healthy populations [3, 5]. More notably, anti-HCV seropositives with detectable serum HCV RNA had a significantly higher risk of dying from any hepatic disease than anti-HCV seropositives with undetectable serum HCV RNA. Our previous report also documented an elevated incidence of hepatocellular carcinoma in anti-HCV seropositives when detectable serum HCV RNA levels were compared to those with undetectable levels [9]. The consistent findings suggest active infection (seropositive for HCV RNA) rather than prior infection (seropositive for anti-HCV) is more important in predicting the long-term risk of mortality from liver diseases.

In this prospective study, HCV infection was associated with an increased mortality from extrahepatic diseases, including circulatory diseases and renal diseases. Chronic HCV infection was associated with an increased (1.4-fold) mortality from circulatory diseases, which was consistent with other reports in Western countries [3, 20]. We have reported that HCV infection was associated with cerebrovascular death after considering for conventional risk factors. The dose–response relationship between serum HCV RNA level and the risk of cerebrovascular death further strengthened the causal association of HCV infection and atherosclerosis [21]. HCV infection may play as a stimulus for atherothrombosis by triggering a cascade of immune and inflammatory responses, either locally within vascular tissue or systematically through inflammatory mediators [22].

Anti-HCV seropositives, particularly anti-HCV seropositives with positive HCV RNA, had an increased risk of dying from renal diseases compared with anti-HCV seronegatives. A large cohort of veterans in the United States found that HCV-infected participants had an increased risk of developing end-stage renal diseases treated with dialysis or renal transplantation [23]. The pathogenesis of HCV-associated renal disease might have resulted from the deposition of circulating immune complexes in the mesangium and subendothelium, which activate the complement system with the proliferation and infiltration of mononuclear phagocytes, enabling the release of protease and oxidants to alter the glomerular permeability [24].

In addition to hepatocellular carcinoma, this study found significant associations between HCV infection and increased mortality from cancers of the esophagus, prostate, and thyroid. A case-control study found an association between HCV and thyroid cancer with a significant odds ratio of 3.3 [13]. Yet, other large-scale prospective studies failed to find the associations [20, 25]. The associations with HCV infection for prostate and esophagus cancer have never been reported previously and need further studies to confirm. Interestingly, all participants who died from these cancers had detectable serum HCV RNA, suggesting that active HCV infection might
play a role. By computerized linkage with national cancer registration profiles, we also found that participants with HCV infection had an increased incidence of esophagus, prostate, and thyroid cancers (data not shown). A large veteran cohort indicated that HCV infection conferred a 20%–30% increased risk of non-Hodgkin lymphoma [25]. In this cohort, only 2 cases died from non-Hodgkin lymphoma and no cases died from Hodgkin’s lymphoma among anti-HCV seropositives. It was difficult to evaluate the association between HCV infection and lymphoma in this study.

Our findings indicate that anti-HCV seropositives with detectable serum HCV RNA had an elevated mortality from several extrahepatic diseases, whereas the risk for anti-HCV seropositives with undetectable HCV RNA had mortality rates much similar to those seronegative for anti-HCV. This suggests that not only hepatic deaths but also extrahepatic deaths could be decreased in anti-HCV seropositives by clearing the virus with efficient antiviral therapy. Our results strengthen the importance of including an HCV RNA test for anti-HCV seropositives in clinical practice. Anti-HCV seropositives, particularly those with detectable serum HCV RNA, should be encouraged to modify health behaviors, including weight reduction, tobacco cessation, or eating a balanced diet, in order to decrease the risk of cancers, circulatory diseases, and renal diseases.

The strength of this study is its generalizability for relatively healthy individuals with chronic HCV infection, particularly for those who acquired HCV via iatrogenic exposures in developing countries. Unlike most Western countries, the most important risk factor of HCV infection in our study population was iatrogenic factors [26–28]. The epidemiological characteristics of HCV infection in Taiwan were similar to those in Japan, Korea, Italy, India, and developing countries [16, 19, 29, 30]. People acquired HCV infection when they received medical or dental procedures, blood transfusion, medical injections, hemodialysis, acupuncture, and similar procedures. Although our study population has a limited generalizability for relatively healthy individuals with chronic HCV infection, particularly for those who acquired HCV via iatrogenic exposures in developing countries.
and effectiveness of chronic hepatitis C management. In addition, the associations between HCV infection and extrahepatic diseases provide insights for future investigations. We classified the risk of hepatic and extrahepatic mortalities for anti-HCV seropositives by including HCV RNA testing, and we also considered other conventional risk factors that have been reported be associated with the diseases. However, some diseases were too rare to derive precise risk estimates associated with HCV infection. A collaborative study with an enlarged sample size is needed to further elucidate the association between HCV infection and rare diseases.

In this community-based cohort study, HCV infection was found to be associated with deaths from hepatic and extrahepatic diseases, particularly for those with detectable serum HCV RNA. It is implied that anti-HCV seropositives should be consulted regarding their elevated risks of both hepatic and extrahepatic diseases. It is also suggested that a serum HCV RNA test with appropriate assay may be helpful to triage HCV-infected patients who need intensive care.

Notes


Financial support. This work was supported by research grants from Department of Health, Executive Yuan, Taipei, Taiwan; Bristol-Myers Squibb Co, United States; Academia Sinica, Taipei, Taiwan; and National Health Research Institutes (NHRI-EX98-9806PI), Chunan, Taiwan.

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References


Appendix